Southborough, Mass.-based SynapDx Corp. has named Thomas Mac Mahon to its board of directors. Mac Mahon was previously president and chief executive of LabCorp. He has also held senior positions at Hoffmann-La Roche Inc. and Roche Diagnostics Group. SynapDx is backed by North Bridge Venture Partners, Bain Capital Ventures and General Catalyst Partners. The company provides laboratory testing services to physicians who evaluate children for developmental disorders.
SynapDx Corporation announced today that Thomas Mac Mahon has joined its board of directors.
Thomas Mac Mahon was President and Chief Executive Officer and a member of the Executive and Management Committees of Laboratory Corporation of America (LabCorp) from January 1997 until his retirement at the end of 2006. Prior to LabCorp, Mr. Mac Mahon was Senior Vice President of Hoffmann-La Roche Inc. (Roche) from 1993 to December 1996 and President of Roche Diagnostics Group from 1988 to December 1996.
Mr. Mac Mahon currently serves on the board of directors of LabCorp. He was Chairman of the Board of Directors of LabCorp from April 1996 until May 2009. He is currently a director of Express Scripts, Inc. and a member of the board of PharMerica Corporation.
About SynapDx Corporation
SynapDx’s mission is to provide laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. Autism Spectrum Disorders are currently estimated to affect 1 in 110 children in the United States according to the Centers for Disease Control.
SynapDx was founded by Stanley Lapidus and closed a Series A round of venture funding in May 2010 from North Bridge Venture Partners, Bain Capital Ventures and General Catalyst Partners. SynapDx’s corporate headquarters is located in Southborough, MA. For more information, please visit: www.synapdx.com.